Pituitary neuroendocrine tumors (PitNETs) constitute a significant proportion of primary intracranial neoplasms and were historically differentiated based on clinical hormone excess syndromes and tinctorial properties. The 5th edition of the WHO classification introduces a paradigm shift towards the lineage-based taxonomy based on the cell-specific expression of transcription factors (TFs). This overview focuses on the biological justifications and diagnostic value of the core TFs of Pituitary-Specific Positive Transcription Factor 1 (PIT1), T-Box Pituitary Transcription Factor (TPIT), and Steroidogenic Factor 1 (SF1), which signify the somatotroph, lactotroph, thyrotroph, corticotroph, and gonadotroph lineages, respectively. By focusing on TF expressions instead of hormone immunoreactivity, pathologists can better subtype clinically non-functioning tumors, effectively relegating the previously overutilized null cell category to about 1% of cases. The TF-based classification is also essential in discriminating high-risk histotypes of silent corticotroph tumors, sparsely granulated somatotrophs, and immature PIT1-lineage PitNETs, which are linked to a higher invasiveness and recurrence. We suggest a practical, stepwise immunohistochemical diagnostic algorithm with the integration of ancillary markers (e.g., GATA3 and ERα) to refine lineage assignment. New molecular correlates such as GNAS and USP8 mutations also add to this framework and guide the use of individualized treatment involving somatostatin analogs or dopamine agonists. And lastly, we discuss the ongoing issues of diagnosis of triple-negative and multilineage tumors and the growing importance of DNA methylation profiling and artificial intelligence in standardized reporting and improving precision management.
Pituitary neuroendocrine tumors (PitNETs) constitute a significant proportion of primary intracranial neoplasms and were historically differentiated based on clinical hormone excess syndromes and tinctorial properties. The 5th edition of the WHO classification introduces a paradigm shift towards the lineage-based taxonomy based on the cell-specific expression of transcription factors (TFs). This overview focuses on the biological justifications and diagnostic value of the core TFs of PIT1, TPIT and SF1 which signify the somatotroph, lactotroph, thyrotroph, corticotroph and gonadotroph lineages respectively. By focusing on TF expressions instead of hormone immunoreactivity, pathologists can better subtype clinically non-functioning tumors, effectively relegating the previously overutilized, null cell category, to about 1% of cases. The TF-based classification is also essential in discriminating high-risk histotypes of silent corticotroph tumors, sparsely granulated somatotrophs, and immature PIT1-lineage PitNETs, which are linked to a higher invasiveness and recurrence. We suggest a practical, stepwise immunohistochemical diagnostic algorithm with the integration of ancillary markers (e.g. GATA3 and ERα) to refine lineage assignment. New molecular correlates such as GNAS and USP8 mutations also add to this framework and guide the use of individualized treatment involving somatostatin analogs or dopamine agonists. And lastly, we discuss the ongoing issues of diagnosis of triple-negative and multilineage tumors and the growing importance of DNA methylation profiling and artificial intelligence in standardized reporting and improving precision management.
The 2021 World Health Organization (WHO) Classification of Tumours of the Central Nervous System introduced three molecularly defined mesenchymal entities: intracranial mesenchymal tumour, FET::CREB fusion-positive (ICMT), defined by fusion of a FET RNA-binding protein gene (EWSR1 or FUS) to a cAMP-response element-binding protein (CREB) family gene; CIC-rearranged sarcoma, defined by fusion of the capicua transcriptional repressor gene (CIC); and primary intracranial sarcoma, DICER1-mutant, defined by mutation of the microRNA-processing gene DICER1. Each is genetically defined yet morphologically non-specific, and each mimics a commoner neoplasm: meningioma, Ewing or embryonal tumour, and high-grade glioma, respectively. This review reads all three through a single mechanistic lens, tracing each defining lesion to its diagnostic phenotype. We compare the available diagnostic modalities and propose a tiered testing algorithm, offered as an expert synthesis rather than a validated pathway. DNA methylation profiling recognises CIC-rearranged and DICER1-mutant sarcoma as distinct classes but has no dedicated class for ICMT, which it may misassign to meningioma, making fusion testing indispensable. Alone among the three, DICER1-mutant sarcoma may arise on a germline background, so its diagnosis should prompt genetic counselling and an offer of germline testing. Molecular characterisation has largely resolved diagnostic ambiguity without yet delivering therapy: candidate targets remain preclinical or anecdotal, and management rests on resection and borrowed adjuvant regimens.
The 2021 WHO Classification of Tumours of the Central Nervous System introduced three molecularly defined mesenchymal entities: intracranial mesenchymal tumour, FET::CREB fusion-positive; CIC-rearranged sarcoma; and primary intracranial sarcoma, DICER1-mutant. Each is genetically defined yet morphologically non-specific, and each mimics a commoner neoplasm: meningioma, Ewing or embryonal tumour, and high-grade glioma respectively. Existing accounts describe these tumours descriptively and in parallel. This review instead reads all three through a single mechanistic lens, tracing each defining lesion to its diagnostic phenotype. We compare the available diagnostic modalities and propose a practical, tiered testing algorithm. Two findings stand out. DNA methylation profiling is the diagnostic backbone for CIC-rearranged and DICER1-mutant sarcoma but has no dedicated class for FET::CREB fusion-positive intracranial mesenchymal tumour, which it actively misassigns to meningioma, making RNA-based fusion testing indispensable. Alone among the three, DICER1-mutant sarcoma may arise on a germline background, so its diagnosis triggers counselling and surveillance for the patient's family. Across all three, molecular characterisation has largely resolved diagnostic ambiguity without yet delivering therapy: mechanistically rational targets remain preclinical, and management rests on resection and borrowed adjuvant regimens. Closing that diagnostic-to-therapeutic gap will require registries, standardised outcome reporting and molecularly stratified trials.
Posterior pituitary and hypothalamic neuronal tumors are uncommon sellar and suprasellar neoplasms that can mimic pituitary neuroendocrine tumors clinically and radiologically. The 5th edition World Health Organization classification (Endocrine and Neuroendocrine Tumors) reinforce a lineage-based framework that separates anterior pituitary tumors from posterior pituitary and hypothalamic neuronal lineages, which is particularly important in hormone-negative lesions and limited tissue samples. This narrative review provides a practical, pathology-centered approach to classification by integrating key anatomic and radiologic clues with histomorphology and targeted immunohistochemistry. We highlight the value and limitations of thyroid transcription factor 1, outline a stepwise workflow incorporating anterior pituitary transcription factors and neuronal differentiation markers, and discuss when vasopressin immunostaining is informative. We also summarize selected molecular insights and clinical management considerations relevant to surgical planning and follow-up.
Posterior pituitary and hypothalamic neuronal tumors are uncommon sellar and suprasellar neoplasms that can mimic pituitary neuroendocrine tumors clinically and radiologically. The 5th edition World Health Organization classifications (Endocrine and Neuroendocrine Tumors) reinforce a lineage-based framework that separates anterior pituitary tumors from posterior pituitary and hypothalamic neuronal lineages, which is particularly important in hormone-negative lesions and limited tissue samples. This narrative review provides a practical, pathology-centered approach to classification by integrating key anatomic and radiologic clues with histomorphology and targeted immunohistochemistry. We highlight the value and limitations of thyroid transcription factor 1, outline a stepwise workflow incorporating anterior pituitary transcription factors and neuronal differentiation markers, and discuss when vasopressin immunostaining is informative. We also summarize selected molecular insights and clinical management considerations relevant to surgical planning and follow-up.